INTRODUCTION
Because Streptococcus pneumoniae is a significant human pathogen, sustained efforts are under way to improve currently available pneumococcal vaccines (Wuorimaa & Kayhty, 2002) . Since all the currently available pneumococcal vaccines provide protection in a serotype-specific manner, an effective vaccine is predicted to reduce the prevalence of pneumococci expressing the serotypes included in the vaccine without reducing the prevalence of the non-vaccine serotypes (Whitney et al., 2003) . Therefore, the efficacy of a vaccine given to a population can be monitored by serotyping pneumococcal isolates from the vaccinated population. Thus an efficient method for serotyping pneumococcal isolates is greatly needed.
Classically, pneumococci are serotyped by the quellung reaction (Henrichsen, 1995; Lund, 1960) . Since the quellung reaction is very labour-intensive and requires a complex array of expensive typing sera, new typing systems have recently been developed to meet the large serotyping needs of vaccine studies. Several groups developed DNAbased typing systems following the determination of the DNA sequence of the capsular biosynthetic gene (cps) loci from strains representing 90 pneumococcal serotypes (Batt et al., 2005; Brito et al., 2003; Kong et al., 2005; Lawrence et al., 2003; O'Halloran & Cafferkey, 2005; Rubin & Rizvi, 2004) . Using extracted DNA, Pai et al. (2006) developed a multiplex PCR for 29 of the pneumococcal serotypes. Other groups developed improved serological assays such as latex agglutination assays (Slotved et al., 2004) and dotblot assays using intact pneumococci (Fenoll et al., 1997) . We developed a multiplex immunoassay for capsular polysaccharides (PSs) using pneumococcal lysates and described an assay employing monoclonal antibodies (mAbs) for 14 common serotypes and polyclonal antibodies for 10 additional serotypes (Yu et al., 2005) .
Experience with our multiplex immunoassay (named the 'multibead assay') showed that PS-coated latex particles are unstable and polyclonal antibodies have limitations in serotype specificity. To extend the usefulness of our multibead assay, we have covalently coupled PS to latex particles and have now developed mAbs to 10 additional serotypes and have characterized them. Additional serotype coverage is important for more detailed coverage, and is potentially of critical importance for serotype surveillance in developing countries. Compared with developing a mAb, developing a PCR for a new serotype is simple. We therefore investigated the new mAbs for the multibead assay method and also investigated combining a PCR method with the multibead method to identify additional serotypes.
METHODS
Bacterial isolates. To determine the assay specificity, we used 147 pneumococcal isolates kept frozen in our laboratory. The laboratory panel includes 90 isolates purchased from the Staten Serum Institut (Copenhagen, Denmark) representing all 90 known pneumococcal serotypes (Henrichsen, 1995) . Also, our laboratory's strain collection includes isolates expressing the 6C serotype, a new serotype that we recently discovered (Park et al., 2007) . For clinical validation, a panel of 157 frozen clinical isolates of pneumococci was obtained from the Centers for Disease Control and Prevention (CDC). The CDC isolates were selected to primarily include the serotypes detected by the new mAbs (Tables 1 and 2 ).
Bacteria were recovered from the frozen isolates by plating scrapings of frozen samples on blood agar plates. After overnight incubation at 37 uC in a candle jar, microtubes containing 500 ml Todd-Hewitt broth with yeast extract (0.5 %) and 0.001 % bromcresol purple per tube were inoculated with a colony of bacteria. After overnight culture at 37 uC in a candle jar, 38 ml lysing solution (0.2 % sodium deoxycholate, 0.02 % sodium dodecyl sulfate, 0.1 % sodium azide, 0.3 M sodium citrate; pH 7.8) was added to each microtube. The microtubes were then incubated at 37 uC for about 1 h to induce lysis of the pneumococci. The resulting bacterial lysates were stored at 220 uC until they were analysed.
PCR. To identify capsule genes by PCR, bacterial lysates were diluted 10-100-fold in water and then subjected to PCR using primers and previously described reaction conditions (Pai et al., 2006) . The capsule-specific PCR also included primers for part of the cpsA gene, to serve as a positive control for the presence of pneumococcal capsule genes from most pneumococcal strains (Bentley et al., 2006) . The reaction products were separated by agarose electrophoresis, stained with ethidium bromide, and visualized under UV light.
Production of mAbs. mAbs were produced as previously described (Yu et al., 2005) . Briefly, mice were immunized with a PS conjugated to a protein, and splenocytes were harvested from immune mice for hybridization with fusion partner cells (SP2/0-Ag14). Primary wells containing antibodies to capsular PS were identified using ELISA (Yu et al., 2005) . Hybridoma cell lines were established by subcloning the cells in the primary wells twice by limiting dilution. The hybridoma cell lines are listed in Table 1 .
Inhibition ELISA for 11A subtypes. While most isolates typed as 11A by the quellung reaction were reactive with the Hyp11AM2 mAb, some were not (Table 2 ). To distinguish between the two subtypes, we named the isolates typed as 11A by both methods as 11Aa and those typed by the quellung reaction alone as 11Ab. To investigate this serological phenomenon, we established 11Aa-or 11Ab-specific inhibition ELISAs, as previously described (Park et al., 2007) . For the 11Aa inhibition ELISA, microwells of ELISA plates were coated with 11Aa PS, which was purchased from the ATCC (Manassas, VA, USA) as 11A PS. To each microwell, variably diluted bacterial lysates and Hyp11AM2 mAb were added. After incubation, unbound mAb was removed, and bound mAb was determined using alkaline phosphatase-conjugated anti-mouse immunoglobulin antibody and nitrophenyl phosphate substrate. For the 11Ab inhibition ELISA, another 11A-specific mAb, Hyp11AM1, was used and the ELISA microwells were coated with 11Ab PS, which was prepared as described below.
Purification of 11Ab PS. 11Ab PS was purified from a 2 l culture of pneumococcal strain CDC3455-06, as previously described (Park et al., 2007) . Briefly, the PS in the bacterial culture supernatant was precipitated with 70 % ethanol and then purified over an ionexchange column (DEAE-Sepharose) and a molecular mass sizing column (Sephacryl S-300). The fractions containing PS were identified by the anthrone reaction (Ashwell, 1957) and inhibition ELISA for 11Ab PS.
Conjugation of PS to latex beads. Two sets of latex beads conjugated with PS were prepared using PSs purchased from the ATCC, except for the 6A and 11Ab PS. 6A PS was obtained from G. Schiffman (Brooklyn, NY, USA) and 11Ab PS was purified as described above. The latex bead sets contained latex beads of different sizes and with different amounts of red fluorescence, which permits one to identify each bead type by flow cytometry. The latex beads included 10 different types of pre-labelled beads, which are available from Bangs Laboratory as the 'QuantumPlex' latex bead set. Others were unstained latex beads with carboxy or amino groups and were also purchased from Bangs Laboratory. In some cases, the unstained beads were stained with 'DiD oil' (an indodicarbocyanine dye from Molecular Probes), as we have previously described (Park et al., 2000) .
The PSs were conjugated to the beads using one of the three methods described below. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) was used to couple PSs of serotypes 6A, 10A, 19A, 19F and 20 to the beads with amino groups, as previously described (Zielen et al., 1996) . Four hundred microlitres of water containing 1 % bead suspension, 10 mg PS ml 21 and 10 mg EDC ml 21 was incubated overnight at 37 uC with shaking. To the reaction mixture was added 100 ml water containing glycine (250 mM) and glucose (250 mM). After 30 min at room temperature (RT), the beads were washed with PBS containing 0.1 % Tween 20, suspended to 10 7 beads ml 21 in storage buffer (PBS, 0.01 % Tween 20, 1 % BSA, 0.02 % azide and 0.1 % glucose), and kept at 4 uC.
The PSs of serotypes 7F and 22F were conjugated using poly-L-lysine (PLL), as previously described (Pickering et al., 2002) . These PSs were conjugated to PLL using cyanuric chloride, and the resulting PS-PLL conjugate was purified over a Sephadex G-25 column. The PS-PLL conjugate was then conjugated to latex beads with carboxy groups using a two-step carbodiimide reaction. Carboxylated microspheres (5610 7 ) were mixed with 5 mg EDC ml 21 and 5 mg Sulfo-NHS ml 21 . After 20 min, the beads were washed and mixed with 500 ml PS-PLL. After 1 h at RT with shaking, the reaction mixture was mixed with 125 ml water containing glycine (250 mM) and glucose (250 mM). After 30 min at RT, the beads were washed with PBS containing 0.1 % Tween 20, suspended to 10 7 beads ml 21 in the storage buffer, and kept at 4 uC.
The PSs of the remaining serotypes were conjugated using 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium (DMTMM), as previously described (Schlottmann et al., 2006) . Two and seventenths millilitres of water containing PS (1 mg ml 21 ) and DMTMM (15 mg ml
21
) was kept at RT for 1 h with shaking. Activated PS was separated from free DMTMM by desalting chromatography, and the fractions containing the activated PS were identified by the anthrone reaction. Two millilitres of activated PS was mixed with 5610 7 beads with carboxy groups and was incubated overnight at RT with mixing. To the reaction mixture was added 500 ml water containing glycine (250 mM) and glucose (250 mM). After 30 min at RT, the beads were washed with PBS containing 0.1 % Tween 20, suspended to 10 7 beads ml 21 in the storage buffer, and kept at 4 uC.
Multibead assay. The assay was performed as described previously using the two sets of latex bead mixture (Park et al., 2000; Yu et al., 2005) . Set 1 contained beads coated with PSs of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 11Ab, 14, 18C, 19A, 19F and 23F . Set 2 contained beads coated with PSs of serotypes 2, 6A, 8, 10A, 11Aa, 12F, 15B, 17F, 20, 22F and 33F. Each set of bead mixture was incubated with a bacterial lysate and an appropriate mixture of mAbs. The bacterial lysate was diluted either 10-fold or 50-fold. After incubation, the 
RESULTS AND DISCUSSION
Development of multibead assays for 10 additional serotypes with 11 mAbs
We have developed mAbs to 10 additional serotypes to replace the polyclonal antibodies that were used for these serotypes in our previous serotyping assays (Lin et al., 2006) . Table 1 lists 11 new mAbs, including the two mAbs for the 11A serotype (bottom half), in addition to the old mAbs against the 14 common serotypes (top half) that have been used previously (Lin et al., 2006) . Two mAbs were chosen for the 11A serotype following our discovery of the two subtypes of 11A, which are described below. Hyp11AM2 is paired to bind to the 11Aa-PS-coated beads included in bead set 2 (11A PS from the ATCC is labelled as 11Aa PS to avoid confusion). Hyp11AM1 is paired with the 11Ab-PS-coated latex beads included in bead set 1.
Cross-reaction patterns of the new mAbs suggest the existence of epitopes that have not yet been identified for pneumococcal PSs. The only epitope known to be expressed on serotypes 39 and 10A is epitope '10d' (Henrichsen, 1995) . However, '10d' is known to be expressed on 10B, and Hyp10AM6 did not cross-react with 10B. Thus Hyp10AM6 may recognize a new epitope shared between only 10A and 39. In addition to this new epitope, we previously noted that Hyp18CM1 and Hyp23FG3 probably define new epitopes (Yu et al., 2005) since 18C-and 23F-specific epitopes were not described in the past (Henrichsen, 1995) . Furthermore, we have recently described a new serotype, 6C, the discovery of which revealed the presence of several new serogroup 6 epitopes (Park et al., 2007) .
In previous multibead assays, latex beads had a short shelflife since PS was passively adsorbed to the beads. To prepare beads with a longer shelf-life, we covalently conjugated PS to the latex beads. Because one single method (the DMTMM method described above) of conjugating PS did not yield acceptable beads for all 25 different PSs, we examined two additional methods of conjugation (the EDC and PLL methods, also described above). Using these methods, we were able to produce PS-conjugated beads that were stable for more than 3 months. In many cases, the beads remained useful for more than 9 months. The sensitivity of the multibead assay was first investigated using purified PSs as inhibitors. Binding of all mAbs could be inhibited by more than 50 % with 0.1 mg homologous PS ml
21
. This sensitivity was sufficient to allow the use of bacterial lysates diluted 10-and 50-fold for multibead assays.
While we were investigating the conjugation methods, we found that the optimal conjugation method was dependent on the mAb itself. For instance, the PLL conjugation method yielded higher binding signals than the EDC conjugation method for mAb Hyp9VM5. However, the EDC method was better than the PLL method for mAb Hyp9VG1 (Fig. 1 ). Analogous differences were observed for mAbs to 22F (Fig. 1) . While these findings indicate that specific conjugation methods should be selected for each mAb, they also suggest that one conjugation method could preserve a specific epitope better than another conjugation method. PS-conjugated latex beads are increasingly used for measuring concentrations of pneumococcal antibodies to many different serotypes using a flow-cytometer-like instrument (e.g. Luminex) (Pickering et al., 2002) . In view of our findings, before adopting a flow-cytometric bead array method for measuring pneumococcal antibody levels, one should carefully investigate the potential that the epitopes can be altered by the method used to conjugate PS to latex beads (Pickering et al., 2002) .
Next, the assay specificity was investigated using a panel of 147 pneumococcal isolates. The panel included 91 pneumococcal isolates representing all 91 currently known serotypes (Park et al., 2007) . All mAbs reacted with the homologous serotype, but several mAbs cross-reacted with other serotypes (Table 1) . For instance, the mAb Hyp10AM6 was reactive with serotype 10A and was also fully cross-reactive with serotype 39. Hyp7FM1 was fully reactive with serotype 7F as well as with serotype 7A, as we previously reported (Yu et al., 2005) . The presence of crossreactions was unambiguous because reactive samples always inhibited more than 67 % and non-reactive samples always inhibited less than 33 %. Consequently, the crossreactions did not hinder serotype determinations.
The only exception to these unambiguous determinations was Hyp15BG5. With this mAb, all 15B isolates in the test panel inhibited more than 67 % and could be identified unambiguously, but its cross-reaction with 15C isolates was highly variable. For instance, many 15C isolates inhibited about 40-60 %, but some 15C isolates inhibited less than 30 %. When Hyp15BG5 was examined with the purified PSs, Hyp15BG5 could be inhibited only by 15B PS and not by 15C PS (data not shown). The contradiction in cross-reactions observed with 15C PS and pneumococcal isolates can be explained since pneumococci expressing 15C can spontaneously convert to the 15B serotype with an estimated frequency of approximately 1 in 250 bacteria (Venkateswaran et al., 1983) due to a genetically unstable acetylation enzyme gene in the cps locus (van Selm et al., 2003) . Thus identification of 15C isolates with Hyp15BG5 is not based on a serological cross-reaction to 15C PS but is instead based on the spontaneous but variable conversion of 15C isolates to 15B isolates.
Use of bacterial lysates for PCR to identify additional serotypes
The multibead assay is limited by the number of available mAbs. Also, the multibead assay did not reliably identify serotype 15C due to variability in the observed crossreactions. To supplement the multibead assay, we studied the usefulness of the bacterial lysates originally prepared for the multibead assays in a multiplexed PCR. We chose to adopt the PCR method for the five serotypes 15A, 15C, 16F, 35B and 38 because a recent CDC survey showed that these five serotypes are more common among the serotypes not covered by the multibead assay (data not shown). As shown in Fig. 2 , the lysates were useful for the multiplexed PCR (Pai et al., 2006) even with 100-fold dilutions. Serotype 15C could be identified with a PCR test for 15B and 15C serotypes (Fig. 2) and its weak reaction with Hyp15BG5.
Also, we could use the lysates for PCRs for different targets, including additional pneumococcal serotype identification sequences (8 and 17F/A), the pneumolysin gene and multilocus sequence typing targets (data not shown) (Enright & Spratt, 1998) . In addition, we found that lysates prepared more than a year ago and kept frozen were useful for PCRs (data not shown). Thus the combination of serological and DNA testing makes the new assay system useful for epidemiological studies as well as for many reference laboratories due to its increased capacity to distinguish many more, if not all 91, serotypes.
Validation of serotypic specificity of the new multibead assay with clinical isolates
To use clinical isolates to validate our multibead assay, we obtained a panel of 157 clinical isolates from the CDC, where they had all been typed by the quellung reaction. The panel was constructed to preferentially include the serotypes that are detected with the new mAbs, and included more than 10 isolates for each serotype in the multibead assay except for serotype 2. The isolates were analysed using the multibead assay. When the results were compared with the results of the CDC's quellung reaction tests, all the results were identical except for four discrepancies (Table 2) . Three discrepancies were observed for serotype 11A, and one discrepancy was found for a strain (sample 3069-06) that was 'non-typable' at the CDC (Table 2) but was found to be weakly positive for serotype 8 at the University of Alabama at Birmingham (UAB). The non-typable strain (3069-06) was further investigated by deriving 20 isolated subcolonies from the parental stock. Fourteen of the subcolonies were non-typable, but six colonies expressed serotype 8.
Pneumococci expressing serotype 8 can spontaneously inactivate their initial transferase gene (cap8E) and lose capsule production by duplicating a large portion of the cap8E gene (Waite et al., 2003) . This mechanism may have been responsible for some of the subcolonies of sample 3069-06 being typed as serotype 8 and others being nontypable. Therefore, we investigated both types of colonies for the size of the cap8E gene using PCR. Our study found that colonies expressing serotype 8 had a normal-sized cap8E gene but that the non-typable colonies did not have a cap8E gene even though they had the pneumococcal cpsA gene (data not shown). Thus this sample harbours two pneumococcal strains: one expressing a non-typable serotype and the other expressing serotype 8.
When the three discrepant 11A isolates were further investigated, they were repeatedly typed as non-typable at UAB (with Hyp11AM2) but were retyped as 11A by the quellung reaction. To investigate discrepancies in 11A serotyping, we labelled the 11A isolates reacting with Hyp11AM2 as 11Aa and the three non-reactive isolates as 11Ab. When we examined the panel of mAbs that we had prepared against 11A, we found that one mAb (Hyp11AM1) bound to the three 11Ab isolates better than to the 11Aa isolates. The three 11Ab isolates inhibited the binding of Hyp11AM1 to 11Ab-coated latex beads but did not inhibit the binding of any other mAbs. Also, no isolates expressing the non-11A serotype could inhibit the binding of Hyp11AM1 to 11Ab-coated latex beads. Thus the multibead assay system based on 26 mAbs could correctly serotype all clinical isolates and also suggested the presence of subtypes among serotype 11A.
Discovery of subtypes among 11A isolates
To quantitatively study the 11A subtypes, we developed an 11A-subtype-specific inhibition ELISA using the two mAbs (Hyp11AM1 and Hyp11AM2) and two subtypes of 11A PS. The 11A PS from the ATCC was inhibitory in the 11Aa assay but not in the 11Ab assay (data not shown). Conversely, 11Ab PS inhibited the 11Ab assay but not the 11Aa assay (data not shown). Consistent with multibead assay results, lysates of the 11D and 11F serotypes inhibited the 11Aa assay, but lysates of 11B and 11C did not (data not shown). None of these lysates inhibited the 11Ab assay (data not shown). When we examined all 12 CDC samples that were identified as 11A by the quellung reaction, six isolates inhibited the 11Aa assay but not the 11Ab assay and three isolates inhibited the 11Ab assay but not the 11Aa assay (Fig. 3) . Interestingly, three isolates could inhibit both the 11Aa assay and the 11Ab assay; an example is shown in Fig. 3 . These results suggest the presence of serological subtypes in serotype 11A. However, we will not propose these subtypes to be new serotypes until the biochemical and genetic bases for the subtypes of 11A are determined.
The potential discovery of serological subtypes within serotype 11A is interesting since this serotype has been extensively investigated. Identification of these new subtypes in the wake of discovering serotype 6C within the well-established serotype 6A (Park et al., 2007) strongly suggests that the quellung reaction based on polyclonal antibodies may provide only limited serological specificity. We anticipate that additional subtypes will be discovered within other established serotypes and potentially among certain non-typable strains.
Operational experience with the hybrid serotyping assay using both multibead and PCR assays
We describe a hybrid serotyping system using both PCR and serological methods that shares the same sample (bacterial lysate). Since its development, our hybrid serotyping assay has already been used for typing more than 1000 samples. The multibead assay is well suited for primary screening since it has high throughput with reproducible results. Once one has appropriate instruments, the multibead assay costs less than PCR since it uses readily available latex particles, uses very small amounts of antibodies, and is highly automated. Indeed, the multibead assay alone is sufficient to determine the efficacy of current pneumococcal vaccines. Although we could serotype the majority of pneumococcal isolates with the multibead assay, the PCR method is a powerful complement in that it is readily adaptable to identify serotypes for which we currently have no serological reagents. This adaptability is useful when the prevalent serotypes are changing as a result of pneumococcal conjugate vaccine usage. We believe that this hybrid system, which shares one common bacterial lysate, has the capability to be highly precise, efficient and useful for laboratories with high-throughput serotyping needs. 
